• Explore /
  • Abstract
  • / Cisplatin-induced tinnitus (CIS-TINN) and patient-reported outcomes in adult-onset cancer survivors.

Cisplatin-induced tinnitus (CIS-TINN) and patient-reported outcomes in adult-onset cancer survivors.

Abstract

Authors

null

Megan Shuey

Vanderbilt University Medical Center, Nashville, TN

Megan Shuey , Victoria Sanchez , Paul C. Dinh Jr., Patrick O. Monahan , Howard D. Sesso , Mary Eileen Dolan , Sophie D. Fossa , Lawrence H. Einhorn , David J. Vaughn , Neil E. Martin , Chunkit Fung , Robert D. Frisina , Lois B. Travis

Organizations

Vanderbilt University Medical Center, Nashville, TN, University of South Florida, Tampa, FL, Indiana University School of Medicine, Indianapolis, IN, Division of Preventive Medicine, Harvard Medical School, Boston, MA, Department of Medicine, University of Chicago, Chicago, IL, National Advisory Unit on Late Effects after Cancer Treatment, Radiumhospitalet, Oslo University Hospital, Oslo, Norway, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, University of Pennsylvania, Philadelphia, PA, Dana Farber Cancer Institute, Boston, MA, J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, Departments of Medical Engineering and Communication Sciences and Disorders, Global Center for Hearing and Speech Research, University of South Florida, Tampa, FL

Research Funding

Other Government Agency

Background: Cisplatin is one of the most used cytotoxic drugs worldwide, but few studies have comprehensively evaluated CIS-TINN in adult-onset cancer survivors. It is critical to identify survivors with high degrees of handicap and related risk factors, as tinnitus (TINN) is strongly related to adverse health outcomes (AHO) including reduced quality of life, and poorer physical and mental health. Methods: Eligible cisplatin-treated testicular cancer survivors (TCS) (aged < 60 y at diagnosis) completed comprehensive, validated health surveys, including the 20-item Tinnitus Primary Function Questionnaire (TPFQ). TPFQ assesses the 4 main TINN-impaired domains (see Table), each with a response metric of 0% (no interference) to 100% interference by TINN, with final impairment groupings of 0-16% (none/minimal), 17-42% (mild/moderate), and 43-100% (significant). TPFQ measures were compared by 2-sided signed-rank tests. Multinomial logistic regression models (adjusted for age, income, education, yrs since therapy, cisplatin dose, BMI, smoking, hypertension, and hearing loss (HL)) tested for associations with TINN severity. Results are shown as OR [95% CI], p-value. Results: Among 213 TCS [median age 46 y (IQR: 38-52 y); median time since therapy: 10.6 y (IQR: 6.8-16.6 y)], the most common AHOs were CIS-TINN (60%), and HL (60%). For TCS with CIS-TINN, the mean degree of reported interference across all TPFQ domains was 21% (median: 15, IQR: 3-33). TCS with CIS-TINN reported significantly greater interference with emotion (median: 22, range 5-40) than with concentration (median 13, IQR: 1.0-37, p = .004), hearing (median: 10, IQR: 0-30, p < .001), and sleep (median: 2.4, IQR: 0-21, p < .001). Conclusions: Following cisplatin chemotherapy, CIS-TINN is a leading AHO and often reported with HL and reduced quality of life. Severe CIS-TINN was associated with greater handicap on the TPFQ as well as with depression, cognitive dysfunction, and hearing aid use. Overall, however, TCS with CIS-TINN and HL reported underutilization of hearing aids.

TCS with TINN that completed TPFQ (N = 126).


TPFQ Domains

Concentration
Emotion
Hearing
Sleep

N
OR†
95% CI
p
N
OR†
95% CI
p
N
OR†
95% CI
p
N
OR†
95% CI
p
TPFQ Impairment Group
Mild-to-moderate
32
2.7
2.0-3.4
.004
47
3.5
2.8-4.3
< .001
32
1.9
1.2-2.6
.06
19
1.4
0.6-2.1
.43
Severe
54
3.9
3.1-4.8
.001
25
5.3
4.3-6.3
.001
20
4.4
3.3-5.5
.008
15
3.2
2.2-4.2
.03

†OR estimate based on comparison to None/Minimal Impairment.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Palliative Care and Symptom Management

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e24089)

DOI

10.1200/JCO.2022.40.16_suppl.e24089

Abstract #

e24089

Abstract Disclosures

Similar Abstracts

First Author: Jinbing Bai

First Author: Matthew I. Milowsky

First Author: Areej El-Jawahri

First Author: Mackenzi Pergolotti